Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Accenture
Cantor Fitzgerald
Fuji
Chinese Patent Office
Cerilliant
Baxter
Moodys
Chubb
Citi

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,095,030

« Back to Dashboard

Summary for Patent: 5,095,030
Title: Wavelength-specific cytotoxic agents
Abstract:A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
Inventor(s): Levy; Julia G. (Vancouver, CA), Dolphin; David (Vancouver, CA), Chow; Jack K. (Vancouver, CA), Sternberg; Ethan (Vancouver, CA)
Assignee: University of British Columbia (Vancouver, CA)
Application Number:07/414,201
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 5,095,030

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,095,030

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Canada556875Jan 19, 1988
8830 0409.5Jan 19, 1988
Japan63-11847Jan 20, 1988
Japan63-181442Jul 19, 1988

International Patents Family Members for US Patent 5,095,030

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0352076 ➤ Subscribe SPC/GB01/005 United Kingdom ➤ Subscribe
European Patent Office 0352076 ➤ Subscribe C300037 Netherlands ➤ Subscribe
European Patent Office 0352076 ➤ Subscribe 2001C/010 Belgium ➤ Subscribe
European Patent Office 0352076 ➤ Subscribe 1/2001 Austria ➤ Subscribe
Australia 3825889 ➤ Subscribe
Canada 1333442 ➤ Subscribe
Canada 1339927 ➤ Subscribe
Germany 3889231 ➤ Subscribe
Germany 10199008 ➤ Subscribe
Germany 68924215 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Deloitte
Moodys
Fuji
Cantor Fitzgerald
Dow
Fish and Richardson
Julphar
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot